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Abstract 
Reimbursable drugs list is built on the principle of essential medicines lists. To avoid 
the negative effects of the pharmaceutical market and help doctors in drug treatment patients 
Experts Committee of WHO in 1977 has drawn Listen model of essential drugs. The concept 
of essential medicines is unanimously accepted by the World Health Assembly on, and the 
list of these medicines was adopted by 120 countries in the world beats. This list is constantly 
revised and improved several times over the years. 
Purpose: The evidences of the violation of the law for informing pharmaceutical service as a 
legal right of pharmacists and as a liability for HII in the case of the approval of the 
reimbursement list for the coming year. 
Method: In the study were required reimbursement lists for the period 2007 - 2011 and the 
price difference for the 10 drugs for this period. Reimbursement lists were analyzed for some 
of its elements: a. number of new drugs that enter the list and the number of drugs are 
removed for the period of mare we study, b. change of prices of 10 drugs that have the 
greatest consumption,  c. I change the order that alternatives to these drugs that were taken in 
the study, d. difference in the price belonging to the patient pay for the same bar. 
Result and Conclusions: In the end, the conclusion was reached that the entry into force and 
the beginning of implementation of the reimbursement list in different months of the year 
without prior notice of changes that were made has caused damage to ALL pharmacies as a 
result of the stock created drugs that had changed the order of the alternatives. Do not 
implement the law in relation to preliminary information pharmacists is put before a fait 
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accompli by not leaving any opportunity to reduce stock or to obtain supplies of the drugs 
that enter the list for the first time or you spend the first alternative ..   
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Introduction 
 Reimbursable drugs list is built on the principle of essential medicines lists. To avoid 
the negative effects of the pharmaceutical market and help doctors in drug treatment patients 
Ekerpeteve Committee of WHO in 1977 has drawn Listen model of essential drugs. The 
concept of essential medicines is unanimously accepted by the World Health Assembly on, 
and the list of these medicines was adopted by 120 countries in the world beats. This list is 
constantly revised and improved several times over the years. Tendency to draw up the list of 
essential nature observed today in all countries of the world, even in developed countries. 
Essential medicines lists are regulations between the needs of the population and the real 
possibility of the cost. Essential drug lists as a list of reimbursable drugs, provide drugs 
necessary for the treatment of patients. In these lists will include alternative medicines, in 
case of lack of efficacy of the drug, allergic reactions and the inability of its use. 
 Reimbursable drugs list changes every year by removing or introducing new drugs, 
changing reference prices or even change the order of the alternatives. 
 Reimbursable drugs list drawn up by the Commission of drafting and reviewing the 
list of drugs reimbursed at the Ministry of Health. Commission presents draft list for the new 
calendar year before the Council of Ministers, together with its financial bill. 
 The responsible institution for adoption and publication of this list has the legal 
obligation to notify interested parties of changes that will be made to the list. This is for two 
reasons: 
1. Not to create medicine stock which will change and alternative price 
2. To create the possibility of supplying pharmacy new medicines that will enter the 
list. 
Material and methods of work 
This study has been based on finding the problems associated with entry into force of 
list of reimbursement for the period 2007 - 2011, Base paper is a survey conducted in 
reimbursement lists for years taken in the study. The survey was carried out is divided into 
three parts. The first part of the survey related to the period when the entering into force of 
these lists. The second part related to the changes that were made to them in terms of new 
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drugs that have entered every year but also changes in prices for drugs that have a high 
intake. The third part relates to the difference in the price you have to pay the patients for the 
same bar or pharmacy loss of movement of the brain these lists year after year. Price 
differences are only made for packaging unit. Drugs that were obtained for the study were 
wider use by patients with chronic diseases who I used it for years. Change is the first 
payment for patients who do not benefit these drugs free seeing how varied this payment for 
the same bar for a one month treatment as awarded and prescriptions with a refund. This 
method of analysis was selected unable to have a full statistics how much is the annual 
consumption of these drugs on a national scale and how is the number of patients who use 
them. 
Results of treatment 
The survey conducted in 30 private entities between the period January 2009 - 
December 2012, entities that have expressed a desire to take the path of certification and 
quality management standard ISO 9001: 2008, shows that 60% of them think they know that 
what quality management, and in connection with the question of whether they know what 
are the principles of quality management only 30% of them claimed, while the question of 
implementing quality management principles, responded positively to only 2.46% of these 
subjects. 
 None of these companies visited is certified to the standard ISO 9001: 2008, only 
20% have appointed quality manager in the company and only four of these subjects stated 
that they use quality management principles. This shows lack and deficiency in quality 
management and quality management standards, mainly standard ISO 9001: 2008 and it does 
not Albanian firms have shown a significant competitive advantage. 
Discussion 
The years will have these changes reflected in the following tables: 
  YEAR 2007 YEAR 2008 YEAR  2009 YEAR 2010 YEAR 2011 
INCREASED drugs 
(new alternatives)       14 21 31 17 24 
LIST enters into force     APRIL    JULY     JUNE     APRIL JUNE 
Table 1.Months of the effective date of the reimbursement list 
 
This table was constructed based on the books for years received reimbursement in the 
study. 
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Reimbursement List YEAR 2007  
 
Table 2. Drugs included in the study, 2007 
 
This table was constructed based on the book of drug reimbursement in 2007 
 Reimbursable drugs list for 2007 are introduced 14 new drugs that were not in the 
previous list of 2006. These are drugs that treat mainly cardiovascular diseases, talasemine 
and drugs antiprostatike. Jane released constraints therefore has expanded the coverage for at 
least 4 important drugs cardiovascular disease, 4 other antiprostatic and neurological drugs, 
antidiabetic etc.. For this year were not analyzed differences and changes in option prices as 
we took as reference year. These changes will we take them into account in the years to come 
then and drugs you have selected. According to the treatment protocol for a month 
recommend family physicians will be calculated difference in patient ALL you need to pay 
for the same bar. Simultaneously in subsequent years will be calculated loss pharmacy drugs 
that change alternative or removed from the list. This difference will be calculated per unit 
packaging. We cannot give the correct value because we do not have inventory for all 
pharmacies in the Republic of Albania, but this calculation will be done if we have been able 
only one pharmacy packaging unit. 
Reimbursement List YEAR 2008  
 
Tab.3 Drugs taken in the study year 2008 
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This table was constructed based on the list of reimbursed drugs in 2008 
 In this year the list I have added 21 new drugs alternatives, which were mainly related 
to heart diseases, diabetes, multiple sclerosis, etc.;, and are replaced 5 drugs with new drugs. 
Were removed a few drugs that are produced or marketed in Albania, for which no alternative 
drugs in the current reimbursement list. U replaced 5 reimbursable drugs list 2007 with other 
dosage form of the same active principle and alternative active principles. These drugs were 
replaced after not being produced and marketed in our country. From the 2007 list are 
removed 9 drugs 
 Referring tab.3 note that we have alternative change to 2 drugs and a drug is removed 
from the list, it only selected drugs to be assessed. Difference in ALL you need to pay a 
patient for the same bar that was alive, in 2007 will be: 
1. Metformine TEVA   60tab   x 2.4 = 144 
2. Urimax 0.4 mg          30tab   x 1. = 51 
Pharmacy for these drugs there is a loss in sales, calculated only for a packaging unit: 
1. Metformine TEVA   90tab   x 2.4 = 216 
2. Urimax 0.4 mg        30tab   x 1.7 = 51 
3. Valpro AD              100tab x 21 = 2100  ( removed from the list ) 
Reimbursement List YEAR 2009 
 
Tab.4 Taken drugs in the study since 2009. 
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This table was constructed based on the list of reimbursed drugs in 2009 
List of medications 2009 is enriched with 31 new drugs (74 drugs trade option) which 
not only increase the number of drugs reimbursed by the Health Insurance Institute, but 
above all improve significantly the quality of service to the public. The 2009 list includes 405 
drugs that are 233 or 944 active principles commercial alternatives. There are introduced for 
the first time that drugs used for chronic diseases such as leukemia, post-transplant infections. 
This list has new combinations of drugs that significantly improve the quality of service for 
the elderly to diseases such as bronchial asthma, epilepsy, etc. In addition to covering new 
diagnoses drugs and new combinations of treatments, in this list are adding new dosage form 
of medicines which are used the most suitable for children, the chronically ill, etc.. 
New alternatives to drugs have had a negative impact in terms of payment of the patients and 
pharmacies economy. Drugs selected according to the table in 2009 will have the following 
changes: 
Patients    
1. Actrapid   4 pena x 6.9 = 27.6 
2. Metformine TEVA 60 tab x 1 = 60 
3. Glifor   60 tab x 1.5 = 90 
4. Metoprolopidl STADA 30 tab x 4.1 = 123 
5. Diovan 80 mg  30 tab x 46.3 = 1389 
6. Urimax  0.4mg  30 tab x 7.3 = 219 
7. Foradil   30cap x 23.2 = 696 
 For pharmacists we will have the following differences: 
1. Actrapid   5pena x 6.9 = 34.5 
2. Metformine Teva  60tab x 1 = 60 
3. Diovan 80mg  30tab x 46.3 = 1389 
4. Foradil   30cap x 23.2 = 696 
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Reimbursement List YEAR 2010  
 
Tab.5 Medicine taken under study since 2010 
 This table was constructed based on the reimbursement list 2010 
 List of reimbursable drugs is enriched with 17 new drugs of which some dosage drugs 
that treat chronic disease, creating the possibility of a better dosing and appropriate for 
patients. These drugs are used for treatment of anemia, chronic renal insufficiency; diabetes 
or pulmonary disease and CA. Drugs selected according to the table in 2010 will have the 
following changes: 
Patients 
Insuman   4 pena x 5.8 = 23.2    
Actrapid   4 pena x 2.6 = 10.4 
Metformine TEVA  60 tab x 0.5 = 30 
Metoprolol  STADA  30 tab x 1.6 = 48 
Nebilet                                    30 tab  x 21.4 = 642 
Valsacor 80mg  30 tab x 0.9 = 27 
Diovan 80 mg   30 tab x 13.1 = 393 
Urimax  0.4mg  30 tab x 17 = 510 
Femara   30 tab x 242.4 = 7272 
Kurovent   30caps x 3.5  = 105     
Foradil    30cap x 8.3 = 249 
For pharmacists we will have the following differences: 
European Scientific Journal  March 2013 edition vol.9, No.9  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
58 
 
Glifor    60 tab x 5.8 = 348 (removed from the list ) 
Metoprolol PROFARMA 30tab x 0.8 = 24 
Valsacor 80mg  30tab x 3.0 = 117 
Femara   30 tab x 193 = 579 
Reimbursement List YEAR 2011  
 
Tab.6 Drugs taken in the study since 2011 
This table was constructed based on the reimbursement list 2011 
Drugs selected according to the table in 2011 will have the following changes: 
Patients 
Insuman   4 pena x 5.9 = 23.6 
Actrapid   4 pena x 6.4 = 25.6 
Metoprolol PROFARMA 30 tab x 4.8 = 144 
Nebivolol STADA  30 tab x 26.2 = 786 
Nebilet   30 tab x 29.8 = 894 
Valsacor 80mg  30 tab x 0.9 = 27 
Co-Diovan 80mg  30 tab x 20.1 = 603 
Tamsudil   30 tab x 1.6 = 48 
Prolosin   30 tab x 0.5 = 15 
Femara   30 tab x 159.5= 4785 
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Valpro TAD   100tab x 0.4 = 40 
Kurovent   30cap x 4.7 = 141 
For pharmacies: 
Metformine TEVA  100tab x 5.8 = 580 (removed from the list ) 
Metoprolol 100mg  30 tab x 15.3 = 459 (removed from the list) 
Tamsudil   30 tab x 0.6 = 18 
Urimax   30 tab x 53.4 = 1602 (removed from the list) 
Valpro TAD   100 tab x 20.8 = 2080 (removed from the list) 
Foradil    30 cap x 9.3 = 279  
 
Conclusions 
First from point of view a pharmacist, but also as a lawyer not to implement EEC 
Directive in this case rests on the pharmacist and patient. I change the reimbursement list, not 
at the beginning of the calendar year but different months has led to problems in which 
medicines pharmacy supplies new list have passed in the first alternative, and you are 
required to be kept condition. With great difficulty lies on drugs that have descended from the 
first alternative we scale down or even in extreme cases are removed from the list without 
prior notice. All these changes are associated with a financial invoice where the greatest 
damage done pharmacy. Analysis of this bill is simple only we take into account that the state 
has levied its tax for the amount drugs pharmacy I remain stock, distribution warehouses are 
paid for the goods they have provided, while pharmacy must keep a stock destined to expire 
then to fail. 
With regard to the damage done to the patient related to his health. Doctors who 
prescribe medications for chronic disease for their patients brought to a drug resort as 
necessary therapeutic or by economic necessity. . In Europe, the main criteria applied in the 
selection of therapeutic drugs, is necessary, and the freedom to choose the doctor's 
competence. In most cases when patients have been treated for several years with the same 
bar very hard to convince that new alternative that those you recommended is the same. Is 
also complicated even more when the doctor goes on to describe the same bar which last or 
alternative which must be paid or has been removed from the reimbursement list. 
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